Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide agonists, which work by stimulating/activating/enhancing the r

Emerging in the arena of weight management therapy, retatrutide is a different method. Beyond many existing medications, retatrutide operates as a twin agonist, at once engaging both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) sensors. This simultaneous activation encourages various helpful effects, including i